Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the Company ...

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange ...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that, as a ...

Maxim lowered the firm’s price target on Cryo-Cell (CCEL) to $8.50 from $9 and keeps a Buy rating on the shares. The company’s Q4 adjusted EBITDA miss was likely due to higher litigation expenses, ...

Reports FY24 revenue $32M vs $31.3M last year. David Portnoy, Cryo-Cell’s (CCEL) Chairman of the Board and Co-CEO remarked, “The Company’s 2024 fiscal results were impacted by continued investments ...

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first ...